DEA Moves to Classify Synthetic 7-OH as Schedule I Amid Rising Deaths and Hospitalizations
核心洞察
The U.S. DEA announced plans to temporarily classify synthetic 7-hydroxymitragynine (搜索) (7-OH) and three related substances as Schedule I controlled substances, citing no accepted medical use and high abuse potential.
Poison center data shows hospitalizations linked to kratom products surged from 43 in 2015 to 538 in 2025, with 7-OH estimated to be 5 to 15 times more potent than morphine.
Multiple deaths have been linked to 7-OH, including a 50-year-old Idaho woman and a Missouri man, prompting wrongful death lawsuits against manufacturers and retailers.
The U.S. Drug Enforcement Administration (搜索) announced on July 1 that it intends to temporarily classify concentrated synthetic 7-hydroxymitragynine (搜索) (7-OH) and three related substances — mitragynine pseudoindoxyl (搜索), MGM-15 (搜索), and MGM-16 — as Schedule I controlled substances, placing them in the same category as heroin and LSD. The move follows a determination by the U.S. Department of Health and Human Services (搜索) that these substances have no currently accepted medical use and a high potential for abuse.
"Today's action targets highly concentrated, synthetic 7-OH products, which pose a growing threat to public safety and health. Temporarily scheduling these substances underscores the emphasis this Administration has put on the safety, health and well-being of the American people," said DEA Administrator Terrance Cole. "This action gives law enforcement and public health partners the tools needed to address this emerging threat."
The DEA emphasized that the scheduling action applies specifically to highly concentrated, synthetic 7-OH products and does not extend to botanical kratom products containing naturally occurring 7-OH below a specified threshold. Once the temporary scheduling order takes effect, the manufacture, distribution, sale, and possession of the covered substances will be subject to federal criminal, civil, and administrative penalties.
A Sharp Rise in Hospitalizations
The regulatory action comes as poison centers and hospitals nationwide report a dramatic increase in severe cases tied to kratom-related products. A study from the Blue Ridge Poison Center at the University of Virginia found 43 hospitalizations linked to kratom products in 2015. By 2025, that number had risen to 538.
"We're talking about something that I've seen anywhere between maybe 5 and 15 times more potent than morphine," said Dr. John Downs, director of the Virginia Poison Center at Virginia Commonwealth University. "I haven't found another poison center director who feels it's appropriate to have this out on the shelves. I think it's time for action to restrict its ability to be purchased."
Dr. Chris Holstege at the Blue Ridge Poison Center described cases where high concentrations and drug interactions proved life-threatening. "We had a patient who thought he was getting something for pain, took one, but the concentration was so high — mixed with the other medications he was on — he became comatose and went on life support for a day," Holstege said. "There was no doubt he was exposed to 7-hydroxymitragynine (搜索)."
Deaths and Legal Action
The Canyon County Coroner in Idaho recently linked the death of 50-year-old Kirsty Boswell to kratom or kratom-like substances, specifically 7-hydroxymitragynine (搜索) and mitragynine pseudoindoxyl (搜索). Her daughters told KTVB that their mother "wasn't the same person at all when she started taking the 7-OHs," noting she had switched from standard kratom powder to 7-OH in February 2025 before her death that same month.
In Missouri, a wrongful death lawsuit was filed July 13 in Jackson County Circuit Court by the family of Joshua Bradley, who allegedly died March 8, 2026, from the toxic effects of 7-OH. The lawsuit claims Bradley repeatedly purchased 7-OH products from Bear Stop Convenience and other retailers between 2025 and 2026, and that stores knowingly sold and promoted the substance despite its addictive nature. The family is seeking damages in excess of $25,000.
A separate wrongful death lawsuit was previously filed over the death of David Thacker, who died in May 2025 from kratom intoxication. Court records showed his blood contained 1,400 nanograms per milliliter of mitragynine at the time of his death.
Potency and Misleading Marketing
The FDA, in a 2025 letter to physicians, warned that 7-OH products had "exploded in popularity" and can contain 7-OH levels up to 500% higher than natural kratom. The agency cited research finding the compound to be roughly 13 times more potent than morphine.
Researchers with the Scientific Association for Botanical Education and Research (SABER) have argued that 7-OH products are "masquerading" as natural kratom products. "These synthetic products are often deceptively marketed as 'natural kratom extracts,' misleading consumers into believing they are purchasing a safer, plant-based product," the organization stated.
Robyn Shinaver, laboratory director and chief toxicologist for the Lucas County Coroner's Office, noted that many users are not seeking a recreational high. "The most common who use it are those who are treating depression, anxiety, ADHD, PTSD. That's like 70 percent of them is who's using it," Shinaver said. "People aren't looking to cross a drug line. They're looking to self-treat really valid, maybe, medical issues."
Clinical Impact and Withdrawal
Dr. Scott Hadland, Chief of Adolescent and Young Adult Medicine at Mass General for Children and Harvard Medical School, reported seeing increasing numbers of young people using 7-OH in his clinic. "Because 7-OH has these opioid properties, they come in to me and they're actually experiencing, in many cases, symptoms of opioid addiction," Dr. Hadland said. "This includes things like withdrawal from opioids or strong cravings to use opioids, such that they find themselves using 7-OH throughout the day to get by."
Nate Kehlmeier, director of business development at Team Recovery, confirmed that providers are seeing a growing number of patients addicted to 7-OH. "If you're using it every single day and your body is dependent on it, you're going to go through withdrawal. You're going to have to go through a detox process. People that come in on kratom are sick. It's no different than opiate withdrawal," Kehlmeier said.
State-Level and Federal Response
In Virginia, a new law took effect July 1 prohibiting the sale of certain kratom and 7-OH products, and requiring kratom products sold in the Commonwealth to carry a warning label stating that kratom may cause dependence and opioid-like withdrawal.
HHS Secretary Robert F. Kennedy Jr., who recommended the scheduling action in 2025, stated: "Today, we're taking action on 7-OH as a critical step in the fight against opioid addiction. We will protect the health of our nation's youth as we advance our mission to Make America Healthy Again."
The 7-HOPE Alliance, an advocacy group opposing an outright ban, argued for regulation rather than prohibition. "We believe adults should continue to have access to these products within a strong regulatory framework that includes age restrictions, accurate labeling, quality manufacturing standards, consumer education, and appropriate warnings," said Executive Director Jackie Subeck.